KRAS and adenocarcinoma: In these specific subtypes of cervical cancer, patients with a KRAS mutation had a worse prognosis.47 Additionally, Wright and co-authors indicated that out of 40 patients with adenocarcinoma, 8.8% presented with KRAS mutations which were not detected in patients with SCC.48 These KRAS mutations were typical G12 and G13 missense mutations within the guanine exchange factor domain.